Biomea Fusion/BMEA

$18.85

11.86%
-
1D1W1MYTD1YMAX

About Biomea Fusion

Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The Company has built FUSION System discovery platform to advance a pipeline of covalent small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical covalent programs for the treatment of select cancers.

Ticker

BMEA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Thomas Butler

Employees

103

Headquarters

Redwood city, United States

Biomea Fusion Metrics

BasicAdvanced
$570.58M
Market cap
-
P/E ratio
-$3.34
EPS
-
Beta
-
Dividend rate

What the Analysts think about Biomea Fusion

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
159.31% upside
High $90.00
Low $10.00
$18.85
Current price
$48.88
Average price target

Biomea Fusion Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-28.4M
14.52%
Profit margin
0%
-

Biomea Fusion Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.81%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.86
-$0.98
-$0.70
-$0.80
-
Expected
-$0.81
-$0.81
-$0.88
-$0.82
-$0.86
Surprise
5.67%
20.9%
-20.01%
-2.81%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Biomea Fusion stock

Buy or sell Biomea Fusion stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing